MARK L. BAUM
Chief Executive Officer and Chairman of the Board of Directors
Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow Health. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder of Eton Pharmaceuticals (NASDAQ: ETON), as well as a founder and board member of Surface Ophthalmics, Melt Pharmaceuticals, and Visionology. From 2014-2017, Mr. Baum was a senior advisor to VC-backed Curology.com. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient/physician accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.
ANDREW R. BOLL
Chief Financial Officer
Andrew R. Boll is one of the founding employees at Harrow Health. As Chief Financial Officer and Corporate Secretary, he oversees the Company’s financial and administrative operations. Mr. Boll has been integral in the evolution of Harrow, as a leader during the company’s initial start-up stage, to its NASDAQ listing, licensing and M&A activities and current commercial stage. Mr. Boll helped form and create Eton Pharmaceuticals, Surface Ophthalmics, Melt Pharmaceuticals, and ImprimisRx. Prior to Harrow, from 2007 to 2011, Mr. Boll worked for an investment company where he oversaw the fund’s accounting, financial analysis, and reporting; he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, LLC, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, Certified Management Accountant and earned his Bachelor of Science degree, summa cum laude, in Corporate and Public Finance.
JOHN P. SAHAREK
John P. Saharek is President of ImprimisRx, a Harrow Health subsidiary. Mr. Saharek has over 30 years of broad experience developing and commercializing pharmaceutical, biologic, surgical device and diagnostic product portfolios. His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products and leading manufacturing, supply chain and quality operations. Over the past 20 years, he has been focused on the ophthalmic segment, where he has established valuable relationships with key opinion leaders and industry contacts. Prior to joining Imprimis in 2013, he served as Head of U.S. Marketing and Strategy for ThromboGenics, developing the commercial strategy and building a team to launch a new biologic into the U.S. market, and was Vice President, Business Development at SurModics, working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives. Early on in his career, he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master of Business Administration from the University of Hartford and a Bachelor’s degree from Central Connecticut State University.
DENNIS E. SAADEH
Chief of Formulation Strategy
Dennis E. Saadeh is the Chief of Formulation Strategy for Harrow Health. A pharmacist by education and training, he has over 20 years of relevant drug development experience in a variety of settings. His current responsibilities include pre-formulation and formulation development for a multitude of drug product candidates. Additionally, he contributes and collaborates with the Harrow intellectual property team, analytical development group, active pharmaceutical suppliers and contract manufacturers to execute company initiatives. Prior to Harrow, from 1996 to 2015, Dr. Saadeh founded Park Compounding, a specialty pharmacy dedicated to the individual needs of integrative practitioners, including the development of many unique formulations that support the treatment of chronic diseases. He has also participated in numerous clinical research studies for clinical research organizations and pharmaceutical companies related to the treatment of a variety of conditions. In 2012, Dr. Saadeh founded Integrative Therapies Institute (ITI), an educational organization bringing together highly specialized lecturers covering medical conditions and treatment protocols at annual conferences. Dr. Saadeh has his Doctor of Pharmacy degree from the University of Southern California and obtained his Fellowship in the American College of Apothecaries in 2005.
ANDREW "DREW" LIVINGSTON
Chief Innovation Officer
Andrew "Drew" Livingston is the Chief Innovation Officer of Harrow Health and co-founder and Chief Executive Officer of Visionology. Mr. Livingston co-founded and served as CEO of Doxy.me Telemedicine, the fastest growing global SaaS telemedicine software that makes it easier and more affordable for healthcare providers to care for their patients anywhere, including rural and underserved areas. Prior to Doxy.me, he served as Head of Marketing, Branding and UX at German online retailing and mail order giant OTTO Group, where he built Yapital, the first European cashless cross-channel payment system. In addition to engagements with Bain & Co., McKinsey, and GLG Group as a telemedicine expert, Drew has been quoted in Brandweek, Adweek, Fox Business News, and the NY Times and was a regular speaker at conferences across the country on topics such as buzz marketing, experiential and engagement marketing.